The US has bought up virtually all stocks for the next three months of remdesivir, one of the two drugs proven to work against COVID-19.
“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.
“We won’t have access to them. That’s the case in the UK and Europe,” he added.
Remdesivir, which was invented for Ebola but failed to work, is produced almost exclusively by US pharmaceutical giant Gilead Sciences – and it has been priced at $2,340 per patient in wealthier nations.
The US has recorded more than 2.5 million confirmed cases of Covid-19.